Dr. Mukul Arvind Gharote – Medical Oncologist
Dr. Mukul Arvind Gharote is a renowned medical oncologist currently serving as a Consultant Medical Oncologist at Medicover Cancer Institute, Maharashtra. With over 19 years of experience in the field, he has established himself as an expert in medical oncology. Dr. Gharote has practiced in various cities across India, contributing to his extensive knowledge and expertise. His clinical skills encompass a wide range of cancer treatments and patient care. Known for his compassionate approach, Dr. Gharote is dedicated to providing personalized care to his patients.
Specializations
Dr. Mukul Arvind Gharote performs major interventions in the following specialties –
- Medical Oncology
Expertise
Dr. Mukul Arvind Gharote has gained expertise in the following major interventions –
- Treatment of Cancer
- Treatment of Tumor
- Chemotherapy
- Targeted therapy Immunotherapy
- Colon & GI Cancer
- Kidney & GU Cancer
- Breast Cancer Treatment
- Lung cancer
- Leukemia
- Lymphoma
- Myeloma
- Pediatric oncology
- Cancer Screening
- Ovary Cancer
- Bone Cancer
- Thyroid Cancer Palliative Treatment Transplant
- Stem Cell Transplantation
- Genitourinary Cancer
Education & Qualifications
- MBBS, Maharashtra University of Health Sciences Nashik, 2004
- DM – Oncology, BJ Medical College, 2015
- MD – General Medicine, JNMC RAIPUR, 2010
Work Experience
- Sahyadri Super Specialty Hospital Nashik
Publications
Dr. Mukul Arvind Gharote has authored several publications including –
- Common Drugs & their anti-cancer Properties
- Amlodipine-induced inhibition of NFAT-2 nuclear translocation and its utility as an additive to immune checkpoint inhibitor
- Role of poly (ADP) ribose polymerase-1 inhibition by nicotinamide as a possible additive treatment to modulate host immune response and prevention of cytokine storm in COVID-19
- Amlodipine-induced inhibition of NFAT-2 nuclear translocation and its utility as an additive to immune checkpoint inhibitor International Journal of Molecular & Immuno Oncology Article in Press
- Volume 1 | Issue 1 | Article 1008 P a g e | 67 Nicotinamide Supplementation in Prevention of Global Covid-19 Transmission
- High-dose nicotinamide, a histone deacetylase inhibitor (Sirtuin-1), can prevent emergence of treatment resistance in chronic myeloid leukemia – A perspective
- Use of five-day chronomodulated prescription of palbociclib as myelopreservation drug along with Topotecan in recurrent extensive stage small cell lung carcinoma – A perspective article
- Post-chemotherapy maintenance treatment by nicotinamide riboside, a poly ADP ribose polymerase 1 inhibitor, in BRCA mutated advanced ovarian cancer – A perspective
- Post chemotherapy maintenance treatment by Nicotinamide riboside , a PARP-1 inhibitor, in BRCA mutated advanced ovarian Cancer – A perspective
Awards & Recognitions
- Speaker at the international conference on blood cancer held in Dubai
Memberships
- European Association of Cancer Research
- American society of clinical oncology ( ASCO)
- INDIAN COOPERATIVE ONCOLOGY NETWORK( ICON)
Languages
- English
- Marathi
- Hindi
Dr. Mukul Arvind Gharote stays updated with the latest advancements in oncology to offer cutting-edge treatments. Dr. Gharote’s work has earned him recognition and respect within the medical community. He is committed to improving cancer care and outcomes for his patients. His experience and dedication make him a valuable asset to Medicover Cancer Institute.